^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib

Excerpt:
Here, we report a patient with NSCLC harboring a novel HIP1-ALK fusion variant (H30; A20). This patient and another patient with EML4-ALK variant 3a/b initially responded sequentially to crizotinib and then alectinib, a next-generation ALK inhibitor, but developed acquired resistance to alectinib with the presence of a mutation in amino acid residue 1171 (I1171N and I1171S respectively)...She had a partial response (PR) although on crizotinib but developed progression after 5 months. She was then enrolled onto the phase 1 dose escalation portion of the alectinib trial...
DOI:
10.1097/JTO.0000000000000368
Trial ID: